Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress.
Conference call details:
4:30 p.m. ET / 1:30 p.m. PT
Dial-in:
U.S./Toll-Free: + 1 833 470 1428
International: + 1 404 975 4839
Passcode: 549600
You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI ® (maralixibat) oral solution/LIVMARLI ® (maralixibat) tablets, CHOLBAM ® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus.
CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease.
CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases.
Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Why Musk's feud with Trump could jeopardize his business empire
Elon Musk, the world's richest man, may have made himself an enemy of the world's most powerful leader. The public blowout between Musk and President Trump is threatening the tech billionaire's businesses, some of which have billions of dollars' worth of federal contracts. Musk's aerospace company SpaceX alone reportedly has at least $22 billion in federal contracts — which Trump had threatened to revoke at the peak of his feud with his former adviser. 'Trump goes after people, companies and organizations he doesn't like,' said Peter Loge, a professor at George Washington University and former senior FDA adviser during the Obama administration. 'As a real estate developer, politician and president, he has used every tool at his disposal to punish people he thinks have wronged him,' Loge added. 'Unless Musk expresses contrition, Trump is likely to hurt him in every way he can think of. If Musk is contrite, he can be welcomed back into the Trump tent.' While the two could reconcile in the future, observers agree the dramatic turn of events leaves Musk's business empire vulnerable to Trump's wrath. Trump, at one point during Thursday's back-and-forth, threatened to cut Musk's government contracts as he called his former adviser 'crazy.' 'The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts. I was always surprised that Biden didn't do it!' Trump wrote in a Truth Social post. Musk, in turn, said he would decommission SpaceX's Dragon spacecraft, which is responsible for ferrying astronauts and cargo to and from the International Space Station. He later backed off, after an X user urged him to 'cool off and take a step back.' The exchange underscored how Musk's business ventures could get caught in the crosshairs of any feud with the president, who is known to have a proclivity for retribution. 'If this turns into a hot war, certainly, the consequences for Musk's business relationship with the federal government could be in peril, or at least significantly complicated,' said GOP strategist and Trump campaign alum Brian Seitchik. The tech billionaire officially departed the White House last week after a four-month stint in government in which he seemed to rarely leave Trump's side, becoming a near constant presence at Mar-a-Lago, Cabinet meetings and the Oval Office. He exited the administration seemingly on good terms with Trump despite his pushback against the president's sweeping tax and spending bill — the centerpiece of Trump's domestic policy agenda, which is projected to add trillions of dollars to the deficit. Trump presented Musk with a golden key to the White House during a Friday farewell ceremony in Oval Office, during which the duo downplayed their differences and spoke highly of each other's work. However, Musk sharpened his criticism of Trump's 'big, beautiful bill' soon after, as he slammed the legislation as a 'disgusting abomination.' The president responded Thursday, saying he was 'very surprised' and 'disappointed' by Musk's comments and cast doubt on the future of their relationship. 'Elon and I had a great relationship. I don't know if we will anymore,' Trump said during an Oval Office appearance alongside German Chancellor Friedrich Merz. The situation quickly devolved into personal attacks. Musk fired back on his social platform X, suggesting the president would have lost the 2024 election without him, linking Trump to disgraced financier Jeffrey Epstein and backing calls for the president's impeachment. As the feud dragged on Thursday, Tesla's stock plunged 14 percent Thursday, costing the electric vehicle maker more than $150 billion. The company was still trying to fully recover from the fallout of Musk's highly controversial role in the Trump administration, leading the Department of Government Efficiency (DOGE). Tesla's stock is down 20 percent since the start of the year. 'The social media and war of words back and forth is not good for anyone and put massive pressure on Tesla shares with fears that Trump will turn from friend to foe and create a tough regulatory environment for Musk in the Beltway,' Wedbush Securities analysts wrote in a note Friday. 'Musk needs Trump and Trump needs Musk for many reasons, and these two becoming friends again will be a huge relief for Tesla shares,' they added. Ross Gerber, a longtime Tesla investor and CEO of Gerber Kawasaki Wealth and Investment Management, slammed Musk for the ripple effects his comments may have had on Tesla's stock. 'Trump is an angry and vindictive man who doesn't forget when slighted. This doesn't get solved other than Elon groveling back and publicly apologizing,' Gerber wrote on X Friday, adding in an earlier post, 'So Tesla investors are down $140 billion over this break up. About how much Musk claimed to saving for the US government.' As the back-and-forth unfolded Thursday, Gerber quipped, 'Can someone please take the phone away from him [Musk].' When pressed on the feud, White House press secretary Karoline Leavitt said Musk has a right to speak for his companies. 'So the only difference between Friday and today is Elon went back to his companies. And, as a businessman, he has a right to speak for his companies. But as president, President Trump has a responsibility to fight for this country,' she said Thursday on FOX News Channel's 'Hannity.' While Trump could pose new risks to Musk's business outlooks, analysts say the fight could also impede the president's ability to run the government. SpaceX held federal contracts with agencies like NASA and the Pentagon long before Trump's presidency, becoming a crucial partner to the federal government as it phased out the space shuttle program. If Musk reverses on his decision to keep Dragon in commission, experts say it could debilitate the U.S. space program 'If such threats were carried out, it would be catastrophic,' said space policy expert Mark Whittington, adding later, 'Without SpaceX, we're back to being dependent on the Russians.' NASA has increasingly relied on SpaceX for its infrastructure, including the Dragon capsule, which is the only U.S. system capable of getting crews to the International Space Station. Russia's Souyuz capsules, the Associated Press reported, are the only other way to get crews to the space station. While both Trump and Musk have much to lose from a war, some Republicans veterans aren't ruling out the chance of a reconciliation. 'There's always the possibility that Trump is serious about this, but I think if you take the 'Art of the Deal' seriously, he is often maximally negotiating,' said GOP strategist Chris Johnson. The feud appeared to cool slightly Friday morning, as Musk seemingly agreed with a post from hedge fund manager Bill Ackman, who suggested the pair 'should make peace for the benefit of our great country.' But Trump has shown no desire to talk to Musk despite reports the two might speak on the phone. 'I won't be speaking to him for a while, I guess, but I wish him well,' Trump told CNN's Dana Bash on Friday. Tesla's stock partially recovered amid hopes of a détente, rising 5 percent. 'If Musk is able to sue for peace and the onus is on him to make peace with Trump, then it'll be a blip in the screen and their bromance will be restored,' Seitchik told The Hill. However, he added, 'If this call goes poorly and this continues to escalate, then certainly Trump will look for every bit of leverage to inflict pain on Elon Musk and his businesses.'
Business Upturn
3 hours ago
- Business Upturn
ProZenith Launches Natural Supplement Formulated for Weight Management Support
By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
4 hours ago
- Yahoo
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
